Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;15(4):416-27.
doi: 10.1634/theoncologist.2009-0325. Epub 2010 Mar 26.

Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety

Affiliations

Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety

David Moreno-Ramirez et al. Oncologist. 2010.

Abstract

Background: Isolated limb perfusion (ILP) involves the administration of chemotherapy drugs directly into a limb involved by locoregional metastases. Unresectable locally advanced melanoma of the limbs represents one of the clinical settings in which ILP has demonstrated benefits.

Methods: A systematic review of the literature on ILP for patients with unresectable locally advanced melanoma of the limbs was conducted. MEDLINE, EMBASE, and Cochrane database searches were conducted to identify studies fulfilling the following inclusion criteria: hyper- or normothermic ILP with melphalan with or without tumor necrosis factor (TNF) or other drugs providing valid data on clinical response, survival, or toxicity. To allocate levels of evidence and grades of recommendation the Scottish Intercollegiate Guidelines Network system was used.

Results: Twenty-two studies including 2,018 ILPs were selected with a clear predominance of observational studies (90.90%) against experimental studies (9.10%). The median complete response rate to ILP was of 58.20%, with a median overall response rate of 90.35%. ILP with melphalan yielded a median complete response rate of 46.50%, against a 68.90% median complete response rate for melphalan plus TNF ILP. The median 5-year overall-survival rate was 36.50%, with a median overall survival interval of 36.70 months. The Wieberdink IV and V regional toxicity rates were 2.00% and 0.65%, respectively.

Conclusions: ILP is effective in achieving clinical responses in patients with unresectable locally advanced melanoma of the limbs. The disease-free and overall survival rates provided by ILP are acceptable. ILP is safe, with a low incidence of severe regional and systemic toxicity.

PubMed Disclaimer

Conflict of interest statement

Disclosures

David Moreno-Ramirez: None; Luis de la Cruz-Merino: None; Lara Ferrandiz: None; Roman Villegas-Portero: None; Adoracion Nieto-Garcia: None.

Section editors Jeffrey Weber and Steven J. O'Day have disclosed no financial relationships relative to the content of this article.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias.

Figures

Figure 1.
Figure 1.
Procedure for the selection of studies included in the systematic review.
Figure 2.
Figure 2.
Clinical effectiveness of isolated limb perfusion with melphalan and melphalan plus TNF. Median values of response are indicated by black squares, and ranges are indicated by grey bars. Abbreviations: CR, complete response; ILP, isolated limb perfusion; NR, no response; OR, overall response; PR, partial response; TNF, tumor necrosis factor.

Similar articles

Cited by

References

    1. Creech JO, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–632. - PMC - PubMed
    1. Creech JO, Krementz ET, Ryan RF, et al. Experiences with isolation-perfusion technics in the treatment of cancer. Ann Surg. 1959;149:627–639. - PMC - PubMed
    1. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg. 1996;83:1319–1328. - PubMed
    1. Benckhuijsen C, Kroon BB, van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol. 1988;14:157–163. - PubMed
    1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–3648. - PubMed

Publication types

MeSH terms

Substances